Avotaciclib

• UNSPSC Description:

  Avotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/avotaciclib.html

• Smiles:

  OC1=CC=C(C2=NC(N)=NC=C2)N=C1C3=NC(N)=NC=C3

• Molecular Weight:

  281.27

• References & Citations:

  [1]Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.

• Shipping Conditions:

  Blue Ice

• CAS Number:

  1983983-41-0